Patients with an aggressive form of bladder cancer could receive treatment in nearly half the time if a cheaper, less-invasive test is used, research has found. Researchers from the University of ...
Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results